Interactions of AChE with Aβ Aggregates in Alzheimer's Brain: Therapeutic Relevance of IDN 5706

Overview

Journal Front Mol Neurosci

Specialty Molecular Biology

Date 2011 Sep 28

PMID 21949501

Citations 56

Authors

Francisco J Carvajal

Nibaldo C Inestrosa

Affiliations

Soon will be listed here.

Abstract

Acetylcholinesterase (AChE; EC 3.1.1.7) plays a crucial role in the rapid hydrolysis of the neurotransmitter acetylcholine, in the central and peripheral nervous system and might also participate in non-cholinergic mechanism related to neurodegenerative diseases. Alzheimer's disease (AD) is a neurodegenerative disorder characterized by a progressive deterioration of cognitive abilities, amyloid-β (Aβ) peptide accumulation and synaptic alterations. We have previously shown that AChE is able to accelerate the Aβ peptide assembly into Alzheimer-type aggregates increasing its neurotoxicity. Furthermore, AChE activity is altered in brain and blood of Alzheimer's patients. The enzyme associated to amyloid plaques changes its enzymatic and pharmacological properties, as well as, increases its resistant to low pH, inhibitors and excess of substrate. Here, we reviewed the effects of IDN 5706, a hyperforin derivative that has potential preventive effects on the development of AD. Our results show that treatment with IDN 5706 for 10 weeks increases brain AChE activity in 7-month-old double transgenic mice (APP(SWE)-PS1) and decreases the content of AChE associated with different types of amyloid plaques in this Alzheimer's model. We concluded that early treatment with IDN 5706 decreases AChE-Aβ interaction and this effect might be of therapeutic interest in the treatment of AD.

Citing Articles

CNEURO-201, an Anti-amyloidogenic Agent and σ1-Receptor Agonist, Improves Cognition in the Mouse Model of Alzheimer's Disease by Multiple Actions in the Pathology.

Martinez-Orozco H, Bencomo-Martinez A, Maya-Arteaga J, Rubio-De Anda P, Sanabria-Romero F, Casas Z Int J Mol Sci. 2025; 26(3).

PMID: 39941068 PMC: 11818425. DOI: 10.3390/ijms26031301.

Cholinergic neurotransmission in the brain of streptozotocin-induced rat model of sporadic Alzheimer's disease: long-term follow up.

Knezovic A, Salkovic-Petrisic M J Neural Transm (Vienna). 2025; .

PMID: 39891708 DOI: 10.1007/s00702-025-02887-2.

Development of coumarin-inspired bifunctional hybrids as a new class of anti-Alzheimer's agents with potent efficacy.

Singh A, Sharma A, Singh K, Kaur K, Mohana P, Prajapati J RSC Med Chem. 2025; .

PMID: 39790122 PMC: 11707525. DOI: 10.1039/d4md00782d.

Metformin Mitigates Trimethyltin-Induced Cognition Impairment and Hippocampal Neurodegeneration.

Taheri M, Roghani M, Sedaghat R Cell Mol Neurobiol. 2024; 44(1):70.

PMID: 39441380 PMC: 11499442. DOI: 10.1007/s10571-024-01502-4.

Ceanothanes Derivatives as Peripheric Anionic Site and Catalytic Active Site Inhibitors of Acetylcholinesterase: Insights for Future Drug Design.

Pastene-Burgos S, Munoz-Nunez E, Quiroz-Carreno S, Pastene-Navarrete E, Espinoza Catalan L, Bustamante L Int J Mol Sci. 2024; 25(13).

PMID: 39000410 PMC: 11242892. DOI: 10.3390/ijms25137303.

References

Camps P, Cusack B, Mallender W, El Achab R, Morral J, Munoz-Torrero D . Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for treatment of Alzheimer's disease. Mol Pharmacol. 2000; 57(2):409-17. View

Soto C, Castano E, Frangione B, Inestrosa N . The alpha-helical to beta-strand transition in the amino-terminal fragment of the amyloid beta-peptide modulates amyloid formation. J Biol Chem. 1995; 270(7):3063-7. DOI: 10.1074/jbc.270.7.3063. View

Cummings J, Schneider E, Tariot P, Graham S . Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology. 2006; 67(1):57-63. DOI: 10.1212/01.wnl.0000223333.42368.f1. View

von Bernhardi R, Alarcon R, Mezzano D, Fuentes P, Inestrosa N . Blood cells cholinesterase activity in early stage Alzheimer's disease and vascular dementia. Dement Geriatr Cogn Disord. 2005; 19(4):204-12. DOI: 10.1159/000083500. View

Mattson M, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel R . beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci. 1992; 12(2):376-89. PMC: 6575616. View

Bissette G, Seidler F, Nemeroff C, Slotkin T . High affinity choline transporter status in Alzheimer's disease tissue from rapid autopsy. Ann N Y Acad Sci. 1996; 777:197-204. DOI: 10.1111/j.1749-6632.1996.tb34419.x. View

Belli M, Ramazzotti M, Chiti F . Prediction of amyloid aggregation in vivo. EMBO Rep. 2011; 12(7):657-63. PMC: 3128957. DOI: 10.1038/embor.2011.116. View

Piazzi L, Cavalli A, Colizzi F, Belluti F, Bartolini M, Mancini F . Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. Bioorg Med Chem Lett. 2007; 18(1):423-6. DOI: 10.1016/j.bmcl.2007.09.100. View

Prusiner S . The prion diseases. Brain Pathol. 1998; 8(3):499-513. PMC: 8098303. View

10.

Geula C, Mesulam M . Cortical cholinergic fibers in aging and Alzheimer's disease: a morphometric study. Neuroscience. 1989; 33(3):469-81. DOI: 10.1016/0306-4522(89)90399-0. View

11.

Geula C, Mesulam M . Cholinesterases and the pathology of Alzheimer disease. Alzheimer Dis Assoc Disord. 1995; 9 Suppl 2:23-8. DOI: 10.1097/00002093-199501002-00005. View

12.

Clos M, Pera M, Ratia M, Roman S, Camps P, Munoz-Torrero D . Effect of acetylcholinesterase inhibitors on AChE-induced PrP106-126 aggregation. J Mol Neurosci. 2006; 30(1-2):89-90. DOI: 10.1385/JMN:30:1:89. View

13.

Dinamarca M, Arrazola M, Toledo E, Cerpa W, Hancke J, Inestrosa N . Release of acetylcholinesterase (AChE) from beta-amyloid plaques assemblies improves the spatial memory impairments in APP-transgenic mice. Chem Biol Interact. 2008; 175(1-3):142-9. DOI: 10.1016/j.cbi.2008.05.026. View

14.

Nitsch R . From acetylcholine to amyloid: neurotransmitters and the pathology of Alzheimer's disease. Neurodegeneration. 1996; 5(4):477-82. DOI: 10.1006/neur.1996.0066. View

15.

Bronfman F, Moechars D, Van Leuven F . Acetylcholinesterase-positive fiber deafferentation and cell shrinkage in the septohippocampal pathway of aged amyloid precursor protein london mutant transgenic mice. Neurobiol Dis. 2000; 7(3):152-68. DOI: 10.1006/nbdi.2000.0283. View

16.

Lee V, Goedert M, Trojanowski J . Neurodegenerative tauopathies. Annu Rev Neurosci. 2001; 24:1121-59. DOI: 10.1146/annurev.neuro.24.1.1121. View

17.

Hainfellner J, Wanschitz J, Jellinger K, Liberski P, Gullotta F, Budka H . Coexistence of Alzheimer-type neuropathology in Creutzfeldt-Jakob disease. Acta Neuropathol. 1998; 96(2):116-22. DOI: 10.1007/s004010050870. View

18.

Diamant S, Podoly E, Friedler A, Ligumsky H, Livnah O, Soreq H . Butyrylcholinesterase attenuates amyloid fibril formation in vitro. Proc Natl Acad Sci U S A. 2006; 103(23):8628-33. PMC: 1482631. DOI: 10.1073/pnas.0602922103. View

19.

Abramov A, Canevari L, Duchen M . Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J Neurosci. 2004; 24(2):565-75. PMC: 6729998. DOI: 10.1523/JNEUROSCI.4042-03.2004. View

20.

Reyes A, Perez D, Alvarez A, Garrido J, Gentry M, Doctor B . A monoclonal antibody against acetylcholinesterase inhibits the formation of amyloid fibrils induced by the enzyme. Biochem Biophys Res Commun. 1997; 232(3):652-5. DOI: 10.1006/bbrc.1997.6357. View